Last year marked an increase in federal securities class action filings, with plaintiffs filing 212 cases in 2023, up from 197 in 2022 and ending an overall decline in filings since 2019. Life sciences companies remained...more
As we close out 2023 and begin the first quarter of 2024, securities and derivative litigation continues to evolve. In this quarterly update, we examine trends in federal securities class action filings, which saw an uptick...more
2/20/2024
/ Banking Sector ,
Biotechnology ,
Class Action ,
Cryptocurrency ,
Derivatives ,
False Statements ,
Infrastructure ,
International Maritime Organization (IMO) ,
Investors ,
Japan ,
Life Sciences ,
Macquarie Infrastructure Corp v Moab Partners LP ,
Philip Morris ,
Private Actors ,
Private Right of Action ,
Regulation S-K ,
Rule 10(b) ,
SCOTUS ,
Securities ,
Securities and Exchange Commission (SEC) ,
Securities Fraud ,
Special Purpose Acquisition Companies (SPACs)
Life sciences companies were popular targets of class action securities lawsuits in 2018.
In the most recent edition of our annual survey, Dechert litigators David H. Kistenbroker, Joni S. Jacobsen and Angela M. Liu examine...more
2/13/2019
/ Anti-Kickback Statute ,
Class Action ,
Clinical Trials ,
FDA Approval ,
Fraud ,
Life Sciences ,
Material Misstatements ,
Mismanagement ,
Misrepresentation ,
Popular ,
Risk Management ,
Risk Mitigation ,
Securities Fraud ,
Securities Litigation ,
Stock Drop Litigation ,
Surveys
2017 was a record year for class action securities litigation, and life sciences companies continued to be popular targets of such lawsuits. During 2017, plaintiffs filed a total of 88 class action securities lawsuits against...more
2/9/2018
/ Bribery ,
Class Action ,
FDA Approval ,
Insider Trading ,
Life Sciences ,
Misrepresentation ,
Motion to Dismiss ,
Pharmaceutical Industry ,
Scienter ,
Securities Fraud ,
Stock Drop Litigation ,
Surveys
Life sciences companies continued to be popular targets of securities fraud class action lawsuits filed in 2016, and prudent life sciences companies should take heed of the results of this year’s decisions. In 2016,...more
3/9/2017
/ Antitrust Violations ,
Class Action ,
Drug Pricing ,
False Statements ,
FDA Approval ,
Generic Drugs ,
Life Sciences ,
Material Misrepresentation ,
Omissions ,
Popular ,
Price-Fixing ,
Promotional Items ,
Risk Mitigation ,
Securities Fraud ,
Stock Drop Litigation